Abstract
Abstract
Objectives
This review intends to provide an overview of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment (HTA) among the different agencies.
Methods
A systematic literature search was performed in MEDLINE and EMBASE databases from inception to July 2020. The studies were eligible for inclusion if they conducted a quantitative analysis of HTA’s previous decisions for cancer drugs. The factors with p-values below the significance level of .05 were considered as the statistically significant factors for HTA decisions.
Results
A total of nine studies for six agencies in Australia, Belgium, France, South Korea, the UK, and Canada were eligible to be included. From the univariable analysis, improvements in clinical outcomes and cost-effectiveness were found as significant factors for the agencies in Belgium, South Korea, and Canada. From the multivariable analysis, cost-effectiveness was found as a positive factor for the agencies in the UK, South Korea, and Canada. Few factors related to characteristics of disease and technology were found to be significant among the included agencies.
Conclusions
Despite the different drug reimbursement systems and the socioeconomic situations, cost-effectiveness and/or improvement on clinical outcomes seemed to be the most important factors for recommendations of cancer drugs among the agencies.
Publisher
Cambridge University Press (CUP)
Reference42 articles.
1. 9. pan-Canadian Oncology Drug Review (pCODR) (2011) pCODR expert review committee deliberative framework [cited September 2021]. Available at: https://www.cadth.ca/sites/default/files/pcodr/The%20pCODR%20Expert%20Review%20Committee%20%28pERC%29/pcodr_perc_deliberative_frame.pdf.
2. Oncology drug health technology assessment recommendations: Canadian versus UK experiences;Chabot;Clinicoecon Outcomes Res.,2014
3. Current challenges in health economic modeling of cancer therapies: A research inquiry;Miller;Am Health Drug Benefit.,2014
4. 4. Swedish Institute for Health Economics (2019) Comparator report on cancer in Europe 2019 – Disease burden, costs and access to medicines [cited September 2021]. Available at: https://ihe.se/en/publicering/comparator-report-on-cancer-in-europe-2019/.
5. Regulatory affairs 101: Introduction to expedited regulatory pathways;Cox;Clin Transl Sci.,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献